PALB2
PALB2 is the essential bridge between BRCA1 and BRCA2 in the homologous recombination (HR) DNA repair pathway. By linking these two master repair proteins, PALB2 ensures the error-free repair of toxic double-strand DNA breaks. Pathogenic mutations significantly increase the risk of breast, ovarian, and pancreatic cancers.
Key Takeaways
- •PALB2 is the essential physical bridge connecting BRCA1 and BRCA2 during homologous recombination (HR) DNA repair.
- •By ensuring error-free repair of double-strand DNA breaks, PALB2 acts as a powerful tumor suppressor.
- •Heterozygous germline mutations confer a high lifetime risk of breast, ovarian, and pancreatic cancers.
- •Tumors lacking PALB2 are profoundly vulnerable to PARP inhibitors and platinum-based chemotherapy (synthetic lethality).
Basic Information
- Gene Symbol
- PALB2
- Full Name
- Partner and Localizer of BRCA2
- Also Known As
- FANCNPNCA3BRCA3
- Location
- 16p12.2
- Protein Type
- DNA Repair Scaffold Protein
- Protein Family
- Fanconi Anemia Core Complex
Related Isoforms
Binds the N-terminus of PALB2, recruiting it to the DNA damage site.
Binds the C-terminus of PALB2, delivering the RAD51 recombinase to the break.
Key SNPs
A common missense variant evaluated in breast cancer risk panels; mostly considered benign but actively studied.
Frequently included in genome-wide association studies for cancer risk.
A well-known founder mutation in certain populations causing severe truncation and high breast cancer risk.
A pathogenic variant causing abnormal splicing, leading to complete loss of PALB2 function.
Overview
PALB2 (Partner and Localizer of BRCA2) is a master scaffolding protein in the cellular DNA damage response. It is the indispensable physical bridge connecting the two most famous breast cancer susceptibility genes: BRCA1 and BRCA2. By orchestrating this complex, PALB2 enables Homologous Recombination (HR)—the cell’s high-fidelity mechanism for repairing highly toxic double-strand DNA breaks.
When a catastrophic DNA break occurs, BRCA1 rushes to the site to sound the alarm and prepare the chromatin. However, BRCA1 cannot fix the DNA alone. It must recruit PALB2 via its N-terminus. PALB2 then acts as a molecular tow truck, using its C-terminus to pull BRCA2 into the nucleus and precisely deliver it to the damaged site. BRCA2 then loads the RAD51 recombinase, which searches the sister chromatid for a perfect template to repair the broken strand. Without PALB2, this entire assembly line fails, forcing the cell to use error-prone backup repair mechanisms that rapidly drive genomic instability and cancer.
Conceptual Model
A simplified mental model for the pathway:
Intentionally simplified; real signaling is shaped by feedback loops, tissue context, and timing.
Core Health Impacts
- • HR repair: Ensures error-free, homologous recombination (HR) repair of DNA breaks.
- • Genomic stability: Maintains overall genomic stability during cellular replication.
- • Fork protection: Protects stalled replication forks from degradation by nucleases.
- • Breast protection: Acts as a highly penetrant tumor suppressor against breast and ovarian cancer.
- • Pancreatic defense: Suppresses the development of familial pancreatic cancer.
Protein Domains
N-Terminal Coiled-Coil
Forms the essential structural interface that binds directly to the coiled-coil domain of BRCA1, recruiting PALB2 to the DNA damage site.
ChAM Domain
The Chromatin Association Motif binds MRG15, an adapter protein that recognizes methylated histones, anchoring the repair complex firmly to the chromatin.
C-Terminal WD40 Repeats
A rigid propeller-like structure that binds BRCA2 and RAD51C. Most pathogenic PALB2 mutations truncate the protein before this domain.
Upstream Regulators
DNA Double-Strand Breaks (DSBs) Activator
The fundamental cellular crisis that triggers the assembly of the Homologous Recombination (HR) repair machinery.
ATM / ATR Kinases Activator
Master damage sensors that phosphorylate numerous targets, including BRCA1 and CHK2, initiating the recruitment cascade.
BRCA1 Activator
The early responder to DSBs; its direct binding to PALB2 is the critical step that recruits it to the damage site.
MRG15 Activator
A chromodomain protein that binds methylated histones (H3K36me3) at active genes, providing an anchor for PALB2.
Downstream Targets
BRCA2 Activates
The essential effector of HR repair. PALB2 binds BRCA2, chaperoning it to the nucleus and delivering it to the DNA break.
RAD51 Activates
The recombinase enzyme. PALB2/BRCA2 complex loads RAD51 onto ssDNA to search for a repair template.
RAD51C Activates
A RAD51 paralog that binds directly to PALB2, essential for the stability of the HR repair complex.
Replication Forks Activates
During S-phase stress, the PALB2/BRCA complex localizes to stalled forks to protect newly synthesized DNA from degradation.
Role in Aging
PALB2 influences aging primarily through the concept of genomic maintenance. Aging is characterized by the slow, inexorable accumulation of DNA damage. A highly efficient HR repair system, dependent entirely on PALB2, is the cell’s best defense against this decay.
Somatic Mutation Accumulation
A decline in HR efficiency with advanced age forces cells to use error-prone repair pathways (like NHEJ). This accelerates the rate at which somatic mutations fix in the genome.
Cellular Senescence
Unrepaired or misrepaired double-strand breaks trigger persistent ATM/p53 signaling. This chronic DNA damage response is one of the primary drivers of permanent cell cycle arrest.
Stem Cell Exhaustion
Adult stem cells are highly sensitive to DNA damage. Without robust PALB2/BRCA-mediated replication fork protection, these pools rapidly accumulate damage and undergo apoptosis or senescence.
Cancer Risk
The most profound consequence of a weakened PALB2 network is the exponentially increased risk of oncogenesis. The loss of high-fidelity repair is the prerequisite for chromosomal rearrangements.
Oxidative Stress Amplification
Age-related oxidative stress causes single-strand breaks. Efficient PALB2 is required to resolve these breaks when they collapse into double-strand breaks at replication forks.
Telomere Maintenance
The HR machinery (including PALB2) plays an accessory role in resolving complex DNA structures at telomeres, helping to delay replicative senescence.
Disorders & Diseases
Familial Breast Cancer
Heterozygous germline mutations confer a 40-60% lifetime risk of breast cancer. Tumors are often aggressive and triple-negative, closely mirroring BRCA1-driven cancers.
Familial Pancreatic Cancer
PALB2 mutations are a major genetic driver of familial pancreatic ductal adenocarcinoma. Carriers have a markedly increased lifetime risk, prompting intensive screening.
Fanconi Anemia (Subtype FA-N)
A devastating, rare childhood disorder caused by inheriting two mutated copies of PALB2. It is characterized by severe developmental abnormalities and bone marrow failure.
Prostate Cancer
Emerging data indicates that pathogenic PALB2 mutations confer an increased risk of aggressive, high-grade prostate cancer in men, similar to the risk profile seen in BRCA2 carriers.
Interventions
Supplements
Crucial for nucleotide synthesis; deficiency increases DNA breaks, placing a higher basal demand on the PALB2/BRCA repair system.
Reduce the basal level of reactive oxygen species (ROS) that cause DNA breaks, easing the overall workload of the HR pathway.
Supports genomic stability and promotes differentiation; adequate levels are associated with better outcomes in cancer risk contexts.
Lifestyle
Minimizing unnecessary medical imaging reduces the induction of complex double-strand breaks that require PALB2 for repair.
Annual breast MRI starting at age 30 and pancreatic cancer screening protocols are critical interventions for mutation carriers.
Risk-reducing mastectomy and salpingo-oophorectomy are discussed options for women with high-penetrance PALB2 mutations.
Medicines
Block single-strand break repair, creating double-strand breaks that the PALB2-deficient tumor cell cannot repair, resulting in synthetic lethality.
Create interstrand DNA crosslinks. Repairing these catastrophic lesions absolutely requires the PALB2/BRCA pathway.
Create replication-associated DNA damage that requires HR for repair; highly toxic to PALB2-deficient cells.
Lab Tests & Biomarkers
Genetic Testing
PALB2 is now routinely sequenced alongside BRCA1 and BRCA2 in all standard germline cancer risk panels.
Next-generation sequencing of tumor DNA identifies somatic PALB2 mutations to qualify patients for PARP inhibitor therapy.
Functional Assays
Genomic scar assays that analyze the tumor genome for massive chromosomal loss-of-heterozygosity (LOH) indicating a broken HR pathway.
A research biomarker; cells lacking functional PALB2 fail to form nuclear RAD51 foci after DNA damage.
Clinical Monitoring
The standard, highly sensitive screening modality recommended annually for healthy female PALB2 carriers starting at age 30.
Hormonal Interactions
Estrogen Proliferative Driver
Drives rapid division in breast and ovarian epithelia, increasing the probability of replication errors and double-strand breaks.
Progesterone Mitogenic In Breast
Can stimulate proliferation in the mammary gland, increasing the replication stress and mutation risk in cells lacking optimal HR repair.
Deep Dive
Network Diagrams
PALB2 Complex Assembly (HR Repair)
Synthetic Lethality: PALB2 Loss and PARP Inhibition
Biochemical Mechanics: Assembling the Bridge
The repair of a double-strand break by Homologous Recombination is an incredibly complex, multi-step process that relies entirely on PALB2 acting as an assembly platform.
1. Resection and Sealing: When a break occurs, the MRE11 complex chews back one strand of the DNA, leaving long tails of single-stranded DNA (ssDNA). These fragile tails are immediately coated and protected by Replication Protein A (RPA).
2. The Hand-off: To repair the break, the cell must swap out the RPA for RAD51, a recombinase that can invade the sister chromatid to find a copy of the missing sequence. This swap requires extreme biochemical force. BRCA1 binds the DNA and recruits PALB2 via its N-terminus.
3. The Delivery: PALB2 acts as the structural linchpin. Using its WD40 domain (at its C-terminus), it pulls BRCA2 to the site. BRCA2 then orchestrates the removal of RPA and the precise loading of RAD51 onto the ssDNA, completing the critical step of HR repair.
Replication Fork Protection
Beyond fixing frank DNA breaks, the PALB2/BRCA complex has a second, equally vital role: protecting DNA replication itself.
Stalled Forks: During S-phase, the replication machinery frequently stalls when it encounters damaged DNA, difficult-to-replicate secondary structures, or when nucleotide pools are low. The stalled fork actually reverses its structure (like a chicken foot) to pause safely.
Nuclease Vulnerability: These reversed forks are highly vulnerable to degradation by cellular nucleases (like MRE11). The PALB2-BRCA2 complex rapidly localizes to these stalled forks, loading RAD51 not for recombination, but as a protective armor to shield the newly synthesized DNA from being chewed up until replication can restart.
Synthetic Lethality and PARP Inhibitors
The most transformative concept in modern oncology is synthetic lethality—the idea that a cancer cell with one broken repair pathway is exceptionally vulnerable if you therapeutically break its backup pathway.
The Setup: Normal cells have two main ways to fix DNA: HR (high fidelity, requires PALB2/BRCA) and Base Excision Repair/Single-Strand Break repair (requires the enzyme PARP1).
The Trap: If a patient has a PALB2 mutation, their normal cells have one good copy of PALB2 and can do HR. Their tumor cells, however, have lost both copies (Loss of Heterozygosity) and cannot do HR. The tumor relies entirely on PARP1 to fix thousands of daily single-strand breaks.
The Kill: When the patient takes a PARP inhibitor (like olaparib), PARP1 is blocked. The single-strand breaks accumulate and, during replication, collapse into double-strand breaks. A normal cell uses its intact PALB2 to fix them via HR and survives. The tumor cell, lacking PALB2, cannot fix them, suffers catastrophic genomic fragmentation, and undergoes apoptosis.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark discovery of PALB2 as the essential partner protein that binds and localizes BRCA2 to sites of DNA damage.
Demonstrated that PALB2 binds BRCA1 and BRCA2 simultaneously, acting as the indispensable physical bridge connecting the HR machinery.
The first major clinical study establishing germline PALB2 mutations as a highly penetrant cause of familial breast cancer.
Identified PALB2 mutations as a significant genetic driver of familial pancreatic cancer, broadening its tumor suppressor role.
Proved that homozygous loss of PALB2 causes Fanconi Anemia, cementing its absolute requirement for genomic stability.
Clinical trial demonstrating the profound efficacy of PARP inhibitors (synthetic lethality) in patients with PALB2-mutated pancreatic cancer.